CoChat

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Introduction. Controversy remains over the optimal length of anticoagulation following idiopathic venous thromboembolism. We sought to determine if a longer, finite course of anticoagulation offered additional benefit over a short course in the initial treatment of the first episode of idiopathic venous thromboembolism. Data Extraction. Rates of deep venous thrombosis, pulmonary embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling patients with first time, idiopathic venous thromboembolism. Data was pooled using random effects meta-regression. Results. Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy was stopped, recurrent venous thromboembolism (0.03 (95% CI: −0.28 to 0.35); ), mortality (−0.10 (95% CI: −0.24 to 0.04); ), and major bleeding (−0.01 (95% CI: −0.05 to 0.02); ) rates measured in percent per patient years, did not significantly change. Conclusions: Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6 months of secondary prophylaxis with vitamin K antagonists. At that time, a decision between continuing with indefinite therapy can be made, but there is no benefit to a longer (but finite) course of therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2010/540386

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1
Figure 1 CC BY · PubMed Central
Figure 2 DVT recurrence rates after treatment cessation.
Figure 2 DVT recurrence rates after treatment cessation.CC BY · PubMed Central
Figure 3 PE recurrence rates after treatment cessation.
Figure 3 PE recurrence rates after treatment cessation.CC BY · PubMed Central
Figure 4 VTE recurrence rates after treatment cessation.
Figure 4 VTE recurrence rates after treatment cessation.CC BY · PubMed Central
Figure 5 Mortality rate
Figure 5 Mortality rateCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. 2006, Cochrane Database of Systematic Reviews
  2. 1999, Statistics in Medicine, 18, 2693, 10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v · doi:10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v
  3. 2004, Saudi Medical Journal, 25, 848

Cited by

See all 12

Metadata

Authors
Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K.
Affiliations
  • Walter Reed National Military Medical Center (US)
  • William Beaumont Army Medical Center (US)
  • Uniformed Services University of the Health Sciences (US)
Corresponding author
Holley, Aaron B.
Venue
Thrombosis
Published
2010-12-29
Volume
2010
Pages
1-9
ISSN
  • 2090-1488 (ISSN-L)
  • 2090-1496
OpenAlex
W1964425295
Cited by
10
References
33
Citations by year
2025: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 1 · 2016: 1 · 2014: 2 · 2013: 1
FWCI
0.07
Type
journal article
Language
en
Open access
Locations
  • Thrombosis (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
Keywords
idiopathic venous thromboembolism, anticoagulation duration, indefinite anticoagulation, vitamin K antagonists, recurrent venous thromboembolism, pulmonary embolism, deep vein thrombosis, major bleeding, mortality, secondary prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.